PURPOSE To evaluate the efficacy of an external carotid artery (ECA) alternative route in intra-arterial chemotherapy (IAC) for treatment of retinoblastoma. METHODS In this retrospective, single-centre, case-control study, 98 retinoblastoma patients who received successful IAC were included. The drug delivery routes were the primary ophthalmic artery (OA) route and the ECA route when OA catheterization was not feasible. RESULTS A total of 337 successful IAC procedures were performed in our study, of which 32 (9.5%) procedures were performed through the ECA route. Eighteen eyes (18.4%) accepted at least one IAC through branches of the ECA. Statistical analysis showed that there was no significant difference in ocular clinical results (enucleation, death, recurrence and event-free) between the ECA and OA routes. No significant association was found between the route of drug delivery and the ocular survival time (p=0.69). The use of ECA catheterization in at least one IAC cycle was not a predictor of enucleation (HR: 1.58; 95% CI: 0.56-4.46, p=0.39). The increasing number of procedures through the ECA route did not increase the risk of enucleation (HR: 1.64; 95% CI: 0.42-6.39, p=0.48). CONCLUSION The ECA alternative route did not affect the efficacy of IAC in retinoblastoma. When the standard OA approach is not feasible, ECA system catheterization should be considered.

中文翻译：

---

视网膜母细胞瘤患者队列中通过眼动脉或颈外动脉传递的动脉内化疗功效的比较

目的评估颈外动脉替代疗法在动脉内化疗（IAC）中治疗视网膜母细胞瘤的疗效。方法在这项回顾性，单中心，病例对照研究中，纳入了成功接受IAC的98例视网膜母细胞瘤患者。当无法进行OA导管插入术时，药物输送途径为主眼动脉（OA）途径和ECA途径。结果我们的研究共进行了337例成功的IAC手术，其中32例（9.5％）通过ECA途径进行。18只眼睛（18.4％）通过ECA的分支接受了至少一个IAC。统计分析表明，ECA和OA途径之间的眼部临床结果（去核，死亡，复发和无事件）没有显着差异。在药物递送途径和眼存活时间之间未发现显着关联（p = 0.69）。在至少一个IAC周期中使用ECA导管插入术并不能预示着晶状体摘除（HR：1.58； 95％CI：0.56-4.46，p = 0.39）。通过ECA途径增加的手术数量并未增加去核的风险（HR：1.64； 95％CI：0.42-6.39，p = 0.48）。结论ECA替代途径不影响IAC在视网膜母细胞瘤中的疗效。当标准的OA方法不可行时，应考虑ECA系统导管插入术。通过ECA途径增加的手术数量并未增加去核的风险（HR：1.64； 95％CI：0.42-6.39，p = 0.48）。结论ECA替代途径不影响IAC在视网膜母细胞瘤中的疗效。当标准的OA方法不可行时，应考虑ECA系统导管插入术。通过ECA途径增加的手术数量并未增加去核的风险（HR：1.64； 95％CI：0.42-6.39，p = 0.48）。结论ECA替代途径不影响IAC在视网膜母细胞瘤中的疗效。当标准的OA方法不可行时，应考虑ECA系统导管插入术。